2025
Relationships between patient‐reported and clinician‐rated toxicities and daily functioning in older adults with advanced cancer undergoing systemic therapy
Culakova E, Mohamed M, Flannery M, Jensen‐Battaglia M, Zhang Z, Ramsdale E, Tylock R, Stauffer F, Wells M, Magnuson A, Loh K, Gada U, Janelsins M, Mohile S. Relationships between patient‐reported and clinician‐rated toxicities and daily functioning in older adults with advanced cancer undergoing systemic therapy. Cancer 2025, 131: e35766. PMID: 39945245, PMCID: PMC11822747, DOI: 10.1002/cncr.35766.Peer-Reviewed Original ResearchConceptsActivities of daily livingInstrumental ADLOlder adultsPatient-reported toxicityAdvanced cancerPhysical performanceActivities of daily living impairmentPRO-CTCAEInstrumental activities of daily livingShort Physical Performance BatteryImpaired activities of daily livingFunctional declineMitigate functional declinePhysical Performance BatteryImpaired instrumental ADLSystemic therapyGeneralized Estimating EquationsClinician-ratedIADL impairmentPerformance BatteryRisk of treatment-related toxicityDaily livingMonths of treatment initiationPatient reportsTreatment-related toxicity
2022
Treatment discontinuation, patient-reported toxicities and quality-of-life by age following trastuzumab emtansine or paclitaxel/trastuzumab (ATEMPT)
Sella T, Zheng Y, Tayob N, Ruddy K, Freedman R, Dang C, Yardley D, Isakoff S, Valero V, DeMeo M, Burstein H, Winer E, Wolff A, Krop I, Partridge A, Tolaney S. Treatment discontinuation, patient-reported toxicities and quality-of-life by age following trastuzumab emtansine or paclitaxel/trastuzumab (ATEMPT). Npj Breast Cancer 2022, 8: 127. PMID: 36450763, PMCID: PMC9712612, DOI: 10.1038/s41523-022-00495-x.Peer-Reviewed Original ResearchHER2-positive breast cancerPatient-reported toxicityPatient-reported outcomesT-DM1Treatment discontinuationTrastuzumab emtansineBreast cancerStage I HER2-positive breast cancerAdjuvant trastuzumab emtansineExcellent disease outcomesLess activity impairmentPaclitaxel/trastuzumabSocial/familyPositive breast cancerSuperior QoLOlder patientsTreatment toleranceTreatment armsTreatment regimensEligible participantsGlobal QOLTherapy optionsActivity impairmentMultivariable modelDisease outcome
2020
RTOG 3506 (STEEL): A study of salvage radiotherapy with or without enzalutamide in recurrent prostate cancer following surgery.
Posadas E, Gay H, Pugh S, Morgan T, Yu J, Lechpammer S, Feng F. RTOG 3506 (STEEL): A study of salvage radiotherapy with or without enzalutamide in recurrent prostate cancer following surgery. Journal Of Clinical Oncology 2020, 38: tps5601-tps5601. DOI: 10.1200/jco.2020.38.15_suppl.tps5601.Peer-Reviewed Original ResearchAndrogen deprivation therapyProgression-free survivalHigh-risk featuresSalvage radiotherapyBiochemical recurrenceRadical prostatectomyProstate cancerSystemic therapyAndrogen receptorYears of androgen deprivation therapyOccurrence of biochemical failureStandard androgen deprivation therapyRandomized phase II studyIndividualization of radiotherapyNon-steroidal anti-androgenPersistently elevated PSADisease control rateRecurrent prostate cancerSeminal vesicle invasionPara-aortic nodesSuspicious lymph nodesPatient-reported toxicityRisk of progressionOne-sided alphaElevated PSA
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply